BD04.03.20
BD and BioGX Inc gave been granted Emergency Use Authorization (EUA) by the FDA for a new diagnostic test that will enable hospitals to screen for COVID-19 (coronavirus) on site and get results in under three hours.
The test helps fill an urgent need across the U.S. for hospitals to access an easy-to-use, rapid diagnostic test to screen patients and health care workers for COVID-19. The test will be run on the BD Max System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. Each unit is capable of analyzing hundreds of samples per day.
"The BioGx molecular test for the BD Max System and our recently announced serology test that can help detect current and past exposure to COVID-19 are part of BD's approach to give health care workers choice and access to the right test for the right situation," said Dave Hickey, president of Integrated Diagnostic Solutions for BD. "We continue to work diligently on an antigen test for our point-of-care BD Veritor System that would complete a full portfolio of COVID-19 tests."
The majority of BD Max Systems are installed in hospital laboratories, reducing the added time and complexity of needing to send samples to a reference lab. The system is fully automated, reducing the opportunity for human error and increasing the speed to result. The System can process 24 samples simultaneously. The tests are expected to add capacity for 50,000 tests per week nationwide.
"The collaboration with BD, combined with the new emergency use authorization process from FDA, enabled our companies to bring a new test to the BD Max System quickly and efficiently," said Shazi Iqbal, Ph.D., CEO of BioGX. "The development and launch speed were critical to ensure hospitals and laboratories can have additional options and capacity for an automated, highly reliable SARS-CoV-2 test for their patients."
BioGX developed the assay for the BD Max System in their Sample-Ready ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC).
The test has been authorized only for the detection of RNA from SARS-CoV-2 virus to aid in the diagnosis of SARS-CoV-2 virus infection, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The test helps fill an urgent need across the U.S. for hospitals to access an easy-to-use, rapid diagnostic test to screen patients and health care workers for COVID-19. The test will be run on the BD Max System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. Each unit is capable of analyzing hundreds of samples per day.
"The BioGx molecular test for the BD Max System and our recently announced serology test that can help detect current and past exposure to COVID-19 are part of BD's approach to give health care workers choice and access to the right test for the right situation," said Dave Hickey, president of Integrated Diagnostic Solutions for BD. "We continue to work diligently on an antigen test for our point-of-care BD Veritor System that would complete a full portfolio of COVID-19 tests."
The majority of BD Max Systems are installed in hospital laboratories, reducing the added time and complexity of needing to send samples to a reference lab. The system is fully automated, reducing the opportunity for human error and increasing the speed to result. The System can process 24 samples simultaneously. The tests are expected to add capacity for 50,000 tests per week nationwide.
"The collaboration with BD, combined with the new emergency use authorization process from FDA, enabled our companies to bring a new test to the BD Max System quickly and efficiently," said Shazi Iqbal, Ph.D., CEO of BioGX. "The development and launch speed were critical to ensure hospitals and laboratories can have additional options and capacity for an automated, highly reliable SARS-CoV-2 test for their patients."
BioGX developed the assay for the BD Max System in their Sample-Ready ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC).
The test has been authorized only for the detection of RNA from SARS-CoV-2 virus to aid in the diagnosis of SARS-CoV-2 virus infection, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
